Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

Resistance to endocrine treatment occurs in ~30% of ER(+) breast cancer patients resulting in ~40,000 deaths/year in the USA. Preclinical studies strongly implicate activation of growth factor receptor, HER2 in endocrine treatment resistance. However, clinical trials of pan-HER inhibitors in ER(+)/H...

Descripción completa

Detalles Bibliográficos
Autores principales: Punturi, Nindo B., Seker, Sinem, Devarakonda, Vaishnavi, Mazumder, Aloran, Kalra, Rashi, Chen, Ching Hui, Li, Shunqiang, Primeau, Tina, Ellis, Matthew J., Kavuri, Shyam M., Haricharan, Svasti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134423/
https://www.ncbi.nlm.nih.gov/pubmed/34011995
http://dx.doi.org/10.1038/s41467-021-23271-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134423/
https://www.ncbi.nlm.nih.gov/pubmed/34011995
http://dx.doi.org/10.1038/s41467-021-23271-0

Ejemplares similares